MBRX

TentativeAI Memo

Moleculin Biotech

As of 2026-08-01/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-01 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

future-looking catalyst discovery is still SERP-only and has not been confirmed by a primary source; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

medium

Horizon

—

Key catalyst

Updated MIRACLE interim dataset • 2026-07-31

Expected move: +5%

Biggest risk

The evidence remains preliminary, prior interim data were reported as not statistically significant, and the company faces near-term financing pressure. No reliable analyst revision, rating-change, or target-change data were available.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

The updated preliminary blinded MIRACLE results show a potentially meaningful AML response signal, including similar response rates in a previously venetoclax-treated subgroup. Confirmation in the full pivotal population could be highly material.

Research note

Recommendation

—

Confidence

medium

As of

2026-08-01

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Clinical-data event volatility
MIRACLE pivotal readout and regulatory progression
Near-term financing and runway event

BearKey bullets

Analyst coverage, options data, short-interest data, and insider-activity evidence were unavailable.
Cash of $10.3 million was disclosed as insufficient for at least one year of planned operations, creating financing and dilution risk [#SEC-10Q-2026-05-14].
Clinical, regulatory, enrollment, and execution outcomes remain uncertain, with no dated pivotal readout or regulatory milestone disclosed.

WatchKey bullets

Updated MIRACLE interim dataset

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $0 (p=50%)

Bull/Bear spread: +200% / -62%

Vs latest close: Bull +200% · Base +5% · Bear -62%

Scenario probabilities

Bull Target: $1 (p=20%)Base Target: $0 (p=50%)Bear Target: $0 (p=30%)

Commentary

News tone is negative-to-mixed because of the reported June 30 selloff, while the July 31 company update provides a potentially constructive but still preliminary clinical signal. No social context, options skew, short-interest, analyst revisions, or trustworthy post-release reaction attribution was available; the appropriate stance is low-confidence event-driven monitoring.

As of 2026-08-01 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Clinical-data event volatility
MIRACLE pivotal readout and regulatory progression
Near-term financing and runway event

Scenarios

Bull Target (Scenario probability)

$1 / p=20% prob

Base Target (Scenario probability)

$0 / p=50% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Price $0 as of 2026-07-31

Nearest Scenario: Base (∆ 5%)

Targets vs latest close: Bull +200% · Base +5% · Bear -62%

Sentiment & Exposure

News Sentiment (30d)

-0.55

Social Sentiment (7d)

Events

Other notable items detected

EVENT2026-07-31
Updated MIRACLE interim dataset
The July 31 8-K reported preliminary blinded results from 62 evaluable subjects in the pivotal Phase 2/3 MIRACLE trial: 24% CR and 37% CRc, with similar rates among patients previously treated with venetoclax-based regimens. The signal is encouraging but remains preliminary and unblinded efficacy confirmation is pending [#8-K-2026-07-31].
Prob 55.00% • Move 35.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Clinical-data event volatility
2026-10-30
A secondary June 30 report described a 25% MBRX decline after interim cancer-trial data fell short of statistical significance, highlighting a fragile near-term trading setup [#SERP-1].
Prob 70% • Move -25% • Priced-in 50%

Long-term Catalysts

Months to a year

MIRACLE pivotal readout and regulatory progression
2027-08-01
The company described MIRACLE as a pivotal adaptive Phase 2/3 trial and stated that future filings and potential FDA or foreign-regulator feedback remain part of the development path. The July 31 filing supplied updated preliminary blinded data, but no dated full readout or regulatory milestone was disclosed [#PR-EARNINGS-2026-07-06] [#8-K-2026-07-31].
Prob 35% • Move 200% • Priced-in 15%
Near-term financing and runway event
2027-08-01
The March 31 10-Q reported $10.3 million of cash, stated that cash was insufficient to fund planned operations for at least one year, and disclosed a need for additional financing. Any financing may extend development but could create substantial dilution [#SEC-10Q-2026-05-14].
Prob 85% • Move -25% • Priced-in 60%

Risks

Analyst coverage, options data, short-interest data, and insider-activity evidence were unavailable.
Cash of $10.3 million was disclosed as insufficient for at least one year of planned operations, creating financing and dilution risk [#SEC-10Q-2026-05-14].
Clinical, regulatory, enrollment, and execution outcomes remain uncertain, with no dated pivotal readout or regulatory milestone disclosed.
Preliminary blinded results may not predict the completed MIRACLE trial; earlier preliminary efficacy commentary explicitly noted limited sample size and lack of statistical significance [#PR-EARNINGS-2026-07-06].
The approximately $2.1 million market capitalization implies extreme liquidity and event-volatility risk.

Peers

Symbol	Summary
CDT	Loose same-sector and market-cap screen candidate; direct indication, modality, and clinical-stage comparability were not established and it was excluded from valuation.
SHPH	Loose same-sector and market-cap screen candidate; direct operating comparability was not established and it was excluded from valuation.
SLXN	Loose same-sector and market-cap screen candidate; useful only for broad event-volatility context, not direct valuation.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-08-01

AI Stock Memo: MBRX - Moleculin Biotech - RankAlpha